| Item Type | Name |
|
Academic Article
|
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
|
|
Academic Article
|
Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer.
|
|
Academic Article
|
Long-term survival and recurrence outcomes following surgery for distal rectal cancer.
|
|
Academic Article
|
Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
|
|
Concept
|
Rectal Neoplasms
|
|
Academic Article
|
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
|
|
Academic Article
|
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
|
|
Academic Article
|
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer.
|
|
Academic Article
|
Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007.
|
|
Academic Article
|
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
|
|
Academic Article
|
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
|
|
Academic Article
|
Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course.
|
|
Academic Article
|
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
|
|
Academic Article
|
Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.
|
|
Academic Article
|
The current landscape of locally advanced rectal cancer.
|
|
Academic Article
|
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
|
|
Academic Article
|
Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
|
|
Academic Article
|
Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer.
|
|
Academic Article
|
Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome.
|
|
Academic Article
|
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
|
|
Academic Article
|
The current state of targeted agents in rectal cancer.
|
|
Academic Article
|
Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer.
|
|
Academic Article
|
Metformin use and improved response to therapy in rectal cancer.
|
|
Academic Article
|
Impact of multimodal therapy in locally recurrent rectal cancer
|
|
Academic Article
|
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy
|
|
Academic Article
|
Hyperfractionated accelerated reirradiation for rectal cancer
|
|
Academic Article
|
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.
|
|
Academic Article
|
Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy.
|
|
Academic Article
|
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity.
|
|
Academic Article
|
Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis.
|
|
Academic Article
|
Neoadjuvant Strategies: Locally Advanced Rectal Cancer.
|
|
Academic Article
|
Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery.
|
|
Academic Article
|
Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer.
|
|
Academic Article
|
TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?
|
|
Academic Article
|
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper.
|
|
Academic Article
|
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
|
|
Academic Article
|
Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis.
|
|
Academic Article
|
Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma.
|
|
Academic Article
|
Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
|
|
Academic Article
|
A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer.
|
|
Academic Article
|
Biologics in rectal cancer.
|
|
Academic Article
|
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
|
|
Academic Article
|
NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.
|
|
Academic Article
|
CLO24-088: Efficacy of Fruquintinib in Less Heavily Pretreated Patients (Pts) With Metastatic Colorectal Cancer (mCRC): Profile-Matched Data From FRESCO and FRESCO-2.
|